Upload
hoangnhi
View
223
Download
2
Embed Size (px)
Citation preview
Draft
The role of paraoxonase 1 in regulating HDL functionality
during aging
Journal: Canadian Journal of Physiology and Pharmacology
Manuscript ID cjpp-2017-0117.R1
Manuscript Type: Review
Date Submitted by the Author: 12-May-2017
Complete List of Authors: Khalil, Abdelouahed; University of Sherbrooke Kamtchueng Simo, Olivier; Universite de Sherbrooke Faculte des Sciences Ikhlef, Souade; Universite de Sherbrooke Faculte de medecine et des sciences de la sante Berrougui, Hicham; Reserch Centre on Aging
Is the invited manuscript for
consideration in a Special Issue?:
IACS Sherbrooke 2016 special issue Part 2
Keyword: HDL functionality, PON1, Cholesterol efflux, aging
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
1
The role of paraoxonase 1 in regulating HDL functionality during aging
Abdelouahed Khalil1,2*, Olivier Kamtchueng Simo1, Souade Ikhlef1 and Hicham Berrougui3
1Research Centre on Aging, Sherbrooke, QC, Canada
2Department of Medicine, Geriatrics Service, Faculty of Medicine and Biological Sciences, University of
Sherbrooke, Sherbrooke, QC, Canada
3Department of Biology, Polydisciplinary Faculty, University Sultan Moulay Slimane, BP 592, 23000 Beni
Mellal, Morocco
* To whom correspondence should be addressed: Abdelouahed Khalil, CdRV-Health Campus, 3001 12th
North Avenue, Sherbrooke, QC, Canada, J1H 4N4. Telephone: 1-819-821-8000, ext. 70148, Email:
Page 1 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
2
Abstract
Pharmacological interventions to increase HDL concentrations have led to disappointing results and
have contributed to the emergence of the concept of HDL functionality. The anti-atherogenic activity of HDL
can be explained by their functionality or quality. The capacity of HDL to maintain cellular cholesterol
homeostasis and to transport cholesterol from peripheral cells to the liver for elimination is one of their
principal anti-atherogenic activities. However, HDL possess several other attributes that contribute to their
protective effect against cardiovascular diseases. HDL functionality is regulated by various proteins and
lipids making up HDL particles. However several studies investigated the role of paraoxonase 1 (PON1) and
suggest a significant role of this protein in the regulation of the functionality of HDL. Moreover, research on
PON1 attracted much interest following several studies indicating that it is involved in cardiovascular
protection. However, the mechanisms by which PON1 exerts these effects remain to be elucidated.
Keywords: HDL functionality, PON1, cholesterol efflux, aging
Page 2 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
3
During the last 20 years, several studies have been interested in the link between paraoxonases (PON),
and more particularly PON1, and the development of cardiovascular diseases (CVD). Results of animal
studies have clearly demonstrated a beneficial role of PON1 by protecting against atherosclerotic plaque
formation. In humans, epidemiological studies have provided convincing evidence for the involvement of
PON1 in the protection against CVD. The decrease of PON1 paraoxonase activity is increasingly
associated with a higher risk of incidence of cardiovascular complications. Moreover, the demonstration that
diet interventions may enhance PON1 activity has generated a huge interest for the development of
pharmacological agent to improve PON1 activity and particularly in the presence of cardiovascular risk
factor. The beneficial effect of PON1 is explained in large part by its ability to regulate the atheroprotective
properties of HDL. However, the mechanism of this regulation is not clearly established. Moreover, PON1 is
only one among the numerous proteins forming HDL. In this review we will discuss the HDL concentration
and HDL function in the protection against CVD. We will focus on the role of PON1 in the regulation of the
functionality of HDL and the mechanisms by which PON1 may regulate the atheroprotective activities of
HDL.
Biogenesis and HDL metabolism: concentration versus functionality
Pre-βHDL are considered the early forms of HDL particles. They result exclusively from the hepatic (~
70%) and intestinal (~ 30%) secretion of apolipoprotein A-I (apoA-I) (Brunham et al. 2006; Timmins et al.
2005). ApoA-I interacts with the ABCAI transporter, which results in its lipidation and the generation of pre-
βHDL, which in turn are gradually transformed into mature HDL by the action of a number of plasmatic
enzymes (Chroni et al. 2003; Haghpassand et al. 2001). During their maturation, HDL are enriched in
cholesterol that is esterified by lecithin cholesterol acyl transferase (LCAT) and transferred back to the liver
for elimination (Tsompanidi et al. 2010). This normal HDL maturation process, which is called reverse
cholesterol transport (RCT), is the only way that excess cholesterol in peripheral tissues can be transferred
Page 3 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
4
to the liver to be metabolized. RCT is one of the main atheroprotective activities of HDL (Esterbauer et al.
1997; Glomset 1968; Johnson et al. 1991).
Epidemiological studies have shown that there is an inverse relationship between HDL concentrations
and the risk of cardiovascular diseases (CVD) (Gordon et al. 1977). However, other studies raise doubts
about the validity of this observation: (1) carriers of the apoA-I Milano mutation have low HDL
concentrations and, paradoxically, enjoy a greater life expectancy and a total lack of atherosclerotic lesions
(Alexander et al. 2009; Frikke-Schmidt et al. 2008; Roma et al. 1993); (2) the Investigation of Lipid Level
Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) study reported a high
mortality risk with Torcetrapib™ despite a 4-fold elevation in normal HDL concentrations (Barter et al. 2007);
(3) an analysis of data from the Framingham study revealed that 44% of CVD occur in subjects with normal
HDL concentrations (Ansell et al. 2003); and (4) several in vitro studies have shown that there is a
significant reduction in the anti-inflammatory and antioxidant activities of HDL during aging, even in the
presence of normal HDL concentrations (Jaouad et al. 2006a; Khalil et al. 1998; Loued et al. 2013). The link
between HDL concentrations and HDL functionality is thus in doubt (Sviridov et al. 2002), and HDL
functionality is increasingly being seen as being more important than HDL concentrations with respect to
cardiovascular protection (Khera et al. 2011).
HDL have a number of potential anti-atherogenic activities, although the relative importance of these
activities remains a subject of debate. HDL possess antioxidant, anti-inflammatory, antithrombotic, and
immunomodulatory activities and also regulate endothelial function (Figure 1). However the participation of
HDL in RCT is one of the most important and least controversial anti-atherogenic activities of HDL. The
RCT activity of HDL is determined in vitro by the measurement of cholesterol efflux capacity from
macrophages and is inversely associated with both carotid intima-media thickness and the likelihood of
angiographic coronary artery disease (Khera et al. 2011).
Page 4 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
5
HDL cholesterol efflux capacity
Cholesterol efflux from macrophages and other tissues is the first and rate-limiting step of RCT (Wang X.
et al. 2007). RCT is modulated by both the predisposition of cells to release cholesterol and by the ability of
HDL to transport cholesterol to the liver for elimination (Yancey et al. 2003). Cholesterol efflux is mediated
via three pathways. The first cellular efflux pathway is via the ATP-binding cassette transporters (ABCA1
and ABCG1). ABCA1 and ABCG1 are members of a large family of ATP-dependent transporters that share
common structural motifs for the active transport of a variety of substrates. Lipid-poor apolipoproteins,
particularly apoA-1, are the preferred cholesterol acceptors for ABCA1 (Wang N. et al. 2000). ABCG1 is
another transporter that promotes mass cholesterol efflux from cells to mature HDL particles (HDL2 and
HDL3) but not to lipid-poor apoA-I (Yvan-Charvet et al. 2010). ABCA1 and ABCG1 promote unidirectional
cholesterol efflux to lipid-poor apoA-I and apoE, and HDL particles, respectively. The second cholesterol
efflux pathway involves the scavenger receptor class B type I (SR-BI). The movement of free cholesterol via
SR-BI is bidirectional and depends on the direction of the cholesterol gradient (Ji et al. 2011). The third
cholesterol efflux pathway is aqueous diffusion. This process involves the desorption of free cholesterol
molecules from donor lipid-water interfaces and the diffusion of these molecules through the intervening
aqueous phase until they collide with and are absorbed by an acceptor (Berrougui et al. 2012). In addition to
the interaction of apoA-1 and mature HDL particles with various membrane proteins, which mediates
cholesterol exchange, other HDL-associated proteins also regulate the cholesterol efflux capacity of HDL,
including lecithin-cholesterol acyltransferase (LCAT), cholesteryl ester transfer protein (CETP), and
paraoxonase (PON1). These proteins also regulate the other anti-atherogenic activities of HDL. A reduction
in their enzymatic activities or protein concentrations may thus significantly impact the functionality of HDL
and their capacity to prevent the initiation of the atherosclerosis process.
Lecithin-cholesterol acyltransferase (LCAT)
Page 5 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
6
LCAT is synthetized principally in the liver and circulates in the plasma associated with HDL (α-LCAT)
and LDL (β-LCAT). LCAT esterifies free cholesterol with phosphatidylcholine, contributing to the formation
of cholesteryl ester and lysophosphatidylcholine (Jonas 2000), the maturation of HDL, and the conversion of
HDL from discoidal to spherical particles. LCAT thus plays an important role in maintaining serum
cholesterol homeostasis by regulating cholesterol transport to the liver. Nevertheless, the role of LCAT in
the pathogenesis of atherosclerosis remains a subject of debate. Animal studies have shown, on the one
hand, that the over-expression of LCAT in transgenic mice significantly increases HDL concentrations and,
surprisingly, the number and size of atherosclerotic lesions in these mice compared to wild-type mice
(Mehlum et al. 1997). The increased atherosclerosis in mice over-expressing LCAT has been explained by
the formation of dysfunctional HDL particles, which are less effective in mediating cholesterol transport to
the liver for elimination (Berard et al. 1997). On the other hand, LCAT knockout mice are more protected
against atherosclerosis than wild-type mice, even when fed a pro-atherogenic diet (Lambert et al. 2001). In
human studies, The Copenhagen City Heart and The Copenhagen General Population studies, which
included more than 50,000 subjects, showed that one of the four common variants of LCAT is responsible
for low HDL concentrations (Haase et al. 2012). However, the significant reduction in HDL concentrations
due to the LCAT variant has no effect on the incidence of CVD (Haase et al. 2012).
An α-LCAT mutation is at the origin of a rare metabolic disorder (fish-eye disease) associated with low
HDL concentrations and a visual complication (Asztalos et al. 2007; Calabresi et al. 2005). Paradoxically,
despite their very low HDL concentrations, individuals with this metabolic disorder have the same risk for
CVD as normal subjects (Calabresi et al. 2009; Calabresi et al. 2012). Interestingly, even though the HDL
concentrations of these individuals is very low, the ability of their HDL to mediate cholesterol efflux is not
affected (Berard et al. 2001; Calabresi et al. 2009; Elkhalil et al. 1997; Tanigawa et al. 2009). In addition,
LCAT-deficient plasma is as efficient as control plasma in mediating cholesterol efflux (Berard et al. 2001).
These results may explain the absence of premature atherosclerosis in LCAT-deficient patients and indicate
Page 6 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
7
that HDL functionality is more important than quantity in terms of cardiovascular protection.
Cholesteryl ester transfer protein (CETP)
CETP is a hydrophobic glycoprotein produced in the liver and secreted into the plasma where it is mainly
associated with HDL (Tall 1993). The importance of CETP in HDL metabolism was first evoked based on a
mutation in the Japanese population whose phenotype is associated with very high HDL concentrations and
a lower incidence of coronary heart diseases (CHD) (Akita et al. 1994; Boekholdt et al. 2003; Inazu et al.
1990; Koizumi et al. 1985). This aroused much interest in developing a CETP inhibitor that would increase
HDL concentrations. Torcetrapib was one of the first CETP inhibitors tested in the ILLUMINATE trial to
determine whether it would decrease cardiovascular events in high-risk populations (Barter et al. 2007).
Torcetrapib, by inhibiting CETP, which normally transfers esterified cholesterol from HDL to other
lipoproteins (LDL and VLDL), increased HDL concentrations by approximately 72% (Barter et al. 2007).
However, despite significantly increasing HDL concentrations, Torcetrapib did not reduce cardiovascular
risk, and the ILLUMINATE trial was terminated because of very serious side effects (Rader 2007).
Nevertheless, the results of the trial contributed to the emergence of the concept of the HDL functionality (or
quality). There is increasing evidence that HDL concentrations do not reflect HDL functionality, which may
be much more important than HDL concentrations in terms of cardiovascular protection (Hiura et al. 2009;
Sviridov et al. 2008). Other studies showed that the 4-fold increase in HDL concentrations observed in
Torcetrapib-treated patients does not improve HDL functionality in terms of the ability of HDL particles to
meditate cholesterol efflux (Yvan-Charvet et al. 2007).
Paraoxonase 1 (PON1)
PON1 is a member of a multigene family that also includes PON2 and PON3. PON1 was initially studied
for its capacity to neutralize organophosphate xenobiotics such as paraoxon, sarin, soman, VX, chlorpyrifos
Page 7 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
8
oxon, diazoxon, and other related toxic compounds. Since all these compounds are non-physiological
substrates, the physiological role of PON1 was not studied at the time. PON1 is a calcium-dependent serum
esterase that is exclusively synthesized in the liver and is found in the bloodstream associated with HDL.
Research on PON1 attracted much interest following several studies indicating that it is involved in
cardiovascular protection (Shih et al. 1998; Tward et al. 2002). PON1-deficient mice are more susceptible to
atherosclerosis, while the over-expression of PON1 in mice increases their resistance to CVD (Shih et al.
1998; Tward et al. 2002). PON1 also prevents the accumulation of oxidized lipids within LDL (Mackness M.
I. et al. 1991). Several studies have contributed to understanding how PON1 prevents the atherosclerosis
process and the associated clinical complications. The anti-atherosclerotic activities of HDL, especially their
antioxidant and anti-inflammatory activities and cholesterol efflux capacity, have been attributed, in large
part, to PON1. However, the mechanisms by which PON1 exerts these effects remain to be elucidated.
Paraoxonase 1 and the antioxidant activity of HDL
Antioxidant activity constitutes one of the anti-atherogenic properties of HDL. Several studies have
shown that HDL prevent the oxidation of LDL both in vitro and in vivo (Bonnefont-Rousselot, Khalil, Gardes-
Albert, et al. 1997). This antioxidant effect was attributed for a long time to vitamin E, particularly α-
tocopherol, which is found in HDL. However, a comparison of the α-tocopherol content of HDL and other
lipoproteins showed that HDL contain the lowest α-tocopherol content (less than one molecule of α-
tocopherol per HDL particle compared to VLDL and LDL, which contain 12 and 45 molecules of α-
tocopherol per particle, respectively) (Bonnefont-Rousselot, Khalil, Delattre, et al. 1997; Romanchik et al.
1995). This clearly indicates that α-tocopherol content alone cannot explain the antioxidant activity of HDL.
A study by Shih et al. demonstrated that the antioxidant effect of HDL is due principally to PON1 (Shih et al.
1998). These authors showed that HDL from PON1 knockout mice lose their capacity to protect LDL against
Page 8 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
9
oxidation, while enriching these HDL with PON1 restores their antioxidant activity (Shih et al. 1998).
Moreover, mice lacking serum PON1 are more susceptible to organophosphate toxicity and atherosclerosis
than wild-type mice (Shih et al. 1998). On the other hand, Tward et al. showed that HDL from mice over-
expressing human PON1 are better able to protect LDL against oxidation and that these mice are more
resistant to atherosclerosis (Tward et al. 2002). In addition, HDL from avian species, which lack
paraoxonase activity, are unable to prevent LDL oxidation in the presence of copper ions (Mackness B. et
al. 1998). We purified PON1 from the plasma of healthy subjects and determined the capacity of human
PON1 to prevent the oxidation of LDL in vitro (Jaouad et al. 2006a). Interestingly, PON1 purified from
human plasma and used at physiological concentrations (40 to 80 g/mL) is more effective in protecting LDL
against oxidation than 50 µM α-tocopherol, which is approximately twice its physiological concentration
(Jaouad et al. 2006a). Nevertheless, the antioxidant activity of PON1 has been questioned in other studies,
which attributed the activity to the contamination of PON1 with platelet-activating factor acetylhydrolase
(PAF-AH) or with tergitol during its purification from plasma (Connelly et al. 2005; Teiber et al. 2004).
However, further studies, including ours, showed that recombinant human PON1 protein also possesses
strong antioxidant activity, which negates the hypothesis that the antioxidant activity is due to contamination
by other plasma proteins (Brushia et al. 2001; Loued et al. 2012). We also showed that the oxidation of
PON1 with oxygen free radicals produced by the gamma radiolysis of water or the incubation of PON1 with
n-ethylmaleimide (NEM) significantly affects its antioxidant activity (Jaouad et al. 2006a). PON1 has a free
sulfhydryl group at position Cys284 that may be involved in its antioxidant activity. The Cys284 residue in
PON1 is one of the amino acids that is modified by oxygen free radicals and by the action of NEM (Jaouad
et al. 2006a). Cys-284 is also the active site for the antioxidant activity of PON1 (Aviram et al. 1998). The
oxidation of Cys-284 can also occur in vivo under oxidative stress conditions, which would affect the
antioxidant activity of PON1 and the anti-atherogenic properties of HDL. In agreement with this, we showed
that the antioxidant activity of PON1 is significantly reduced with aging and that this is due to a decrease in
Page 9 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
10
the number of free sulfhydryl groups on the PON1 of elderly subjects compared to young subjects (Jaouad
et al. 2006b). The paraoxonase activity of PON1 is also lower in elderly subjects. However, this decrease
cannot be explained by a reduction in its plasma concentration or a decrease in HDL concentrations (Seres
et al. 2004). The oxidative stress conditions that characterize the aging process may explain the decrease
in PON1 paraoxonase activity in the elderly (Seres et al. 2004). The susceptibility of HDL to lipid
peroxidation also increases with age (Khalil et al. 1998). The fact that PON1 is exclusively associated with
HDL and that it exhibits antioxidant activity suggests that the increase with aging of the susceptibility of HDL
to lipid peroxidation is largely due to an alteration of PON1 activity (Seres et al. 1996). The decrease in
PON1 activity has an impact on HDL functionality and may explain, at least in part, the development of the
atherosclerosis process in the presence of cardiovascular risk factors such as aging, diabetes, obesity, and
renal failure (Bounafaa et al. 2014; Cherki et al. 2007; Gbandjaba et al. 2012).
PON1 and inflammation
PON1-deficient mice display increased vascular inflammation and thrombogenesis, suggesting that
PON1 has anti-inflammatory activity (Ng et al. 2008). PON1 also has phospholipase-like activity that allows
it to hydrolyze phosphatidylcholine core aldehydes and to produce lysophosphatidylcholine (LysoPC) and
free oxidized fatty acids (Ahmed et al. 2002; Loued et al. 2012). It has been suggested that the hydrolysis of
these oxidized phospholipids may explain the anti-inflammatory activity of PON1 (Ahmed et al. 2003).
Intriguingly, the hydrolysis of oxidized phospholipids in oxLDL contributes to the formation LysoPC and
oxidized free fatty acids, both of which are pro-inflammatory (Ahmed et al. 2002; Rozenberg et al. 2003;
Schilling et al. 2009). This raises the question of how PON1 exerts its anti-inflammatory activity. In a recent
study, we measured the capacity of PON1 to hydrolyze oxidized phospholipids in oxLDL and oxHDL (Loued
et al. 2012). The addition of PON1 to oxLDL contributed to the hydrolysis of oxidized phospholipids and
significantly stimulated the production of LysoPC (Loued et al. 2012). On the other hand, the addition of
Page 10 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
11
PON1 to oxHDL resulted in a concentration-dependent reduction in the production of LysoPC (Loued et al.
2012). These results were confirmed by measurements of endothelial cell-associated intercellular adhesion
molecule 1 (ICAM1) expression. The incubation of PON1 with oxLDL resulted in a significant increase in
ICAM1 expression on endothelial cells, suggesting that PON1 possesses pro-inflammatory activity (Loued
et al. 2012), while incubating PON1 with HDL resulted in a significant decrease in ICAM1 expression on
endothelial cells, suggesting that PON1 also possesses anti-inflammatory activity (Loued et al. 2012). This
discrepancy can be explained by the fact that the anti-inflammatory effect of PON1 depends on its
association with HDL (Loued et al. 2012). PON1 interacts with other lipoprotein components to hydrolyze
and inactivate oxidized phospholipids. These interactions appear to be an intrinsic property of HDL (Loued
et al. 2012). α-LCAT may be one of the HDL-associated enzymes that interact with PON1 to reduce the
pro-inflammatory effect of oxidized lipids. oxHDL alone has a pro-inflammatory effect as measured by
ICAM1 expression on endothelial cells, while the enrichment of oxHDL with PON1 (20 µg/mL) reduces
ICAM1 expression (Figure 2). Interestingly, the anti-inflammatory activity of PON1 increases when LCAT (5
µg/mL) is added to the mixture (Figure 2). We hypothesize that LCAT, due to its lysolecithin acyltransferase
II (LATII) activity, may interact with PON1 by esterifying LysoPC with fragmented acyl groups from oxidized
phospholipids, thus reducing the pro-inflammatory activity of HDL (Goyal et al. 1997; Subbaiah et al. 1996).
PON1 also reduces monocyte chemotaxis and adhesion to endothelial cells (Ahmed et al. 2003), which may
be due to the capacity of PON1 to inhibit the biological activities of oxidized phospholipids and their
hydrolytic products (Ahmed et al. 2003). In addition to its capacity to hydrolyze oxidized lipids, PON1 also
suppresses the pro-inflammatory response of macrophages. This activity may be mediated via its
interaction with the SR-BI receptor on macrophages (Aharoni et al. 2013). We showed that the decrease in
the enzymatic activity of PON1 in elderly subjects significantly affects its anti-inflammatory activity (Loued et
al. 2013). HDL obtained from elderly subjects have a lower capacity to reduce ICAM1 expression on
endothelial cells than HDL obtained from young subjects (Loued et al. 2013). The enrichment of HDL with
Page 11 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
12
PON1 increases the anti-inflammatory activity of HDL as determined by the measurement of ICAM1
expression (Figure 2). Interestingly, extra virgin olive oil consumption enhances the enzymatic activity of
PON1 and the anti-inflammatory activities of both PON1 and HDL (Loued et al. 2013).
PON1 and the capacity of HDL to mediate cholesterol efflux
Although the ability of HDL to mediate cellular cholesterol efflux and transport cholesterol to the liver for
elimination is considered the main anti-atherogenic activity of HDL, very few studies have investigated the
role that PON1 may play in this process. The results of one in vitro study suggested that PON1 stimulates
cholesterol efflux from macrophages (Rosenblat et al. 2006) and that this efflux depends, in part, on the
capacity of PON1 to increase LysoPC formation, which may stimulate HDL binding to macrophages
(Rosenblat et al. 2006). PON1 purified from human plasma enhances cholesterol efflux from J774
macrophages and THP-1 macrophage-like cells (Berrougui et al. 2012). This effect increases with the level
of expression of the ABCA1 transporter on macrophages, suggesting that PON1 may stimulate cholesterol
efflux via an interaction with this transporter (Berrougui et al. 2012). ApoA-I is the only protein associated
with HDL that is known to interact with the ABCA1 transporter and to initiate cholesterol efflux. De Beer et
al. showed that, under inflammatory conditions, serum amyloid A (SAA) has an apoA-I-like effect by
mediating cholesterol efflux via the ABCA1 and ABCG1 transporters (de Beer et al., 2011). Remaley et al.
showed that ABCA1-mediated cellular binding to apolipoproteins and lipid efflux is not specific to apoA-I but
can also occur with other apolipoproteins that contain multiple amphipathic helical domains (Remaley et al.
2001). In addition, the apoA-I mimetic peptide has no sequence homology with the apoA-I protein but
mimics the class A amphipathic helixes and interacts with ABCA1 to promote cholesterol efflux via this
pathway (Xie et al. 2011). PON1, like apoA-I and SAA, also contains an amphipathic α-helix with
approximately 22 amino acids in its secondary structure that enables HDL particles to tightly bind to and
stabilize PON1 and stimulate its activity (Gu et al. 2016; Harel et al. 2004; Perez-Jimenez et al. 2005). The
Page 12 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
13
presence of this structure strengthens the hypothesis that an interaction between PON1 and ABCA1
mediates cholesterol efflux. We showed that PON1 purified from human plasma uses an apoA-I-like
mechanism to modulate cholesterol efflux from rapid and slow efflux pools derived from the lipid raft and
non-raft domains of the plasma membrane, respectively (Berrougui et al. 2012). PON1 also stimulates the
expression of ABCA1 on macrophages (Berrougui et al. 2012), which may be due to the capacity of PON1
to hydrolyze oxidized phospholipids in oxLDL and to the formation of LysoPC (Ikhlef et al. 2016). A pre-
treatment of oxLDL with PON1 followed by an incubation with cholesterol-loaded macrophages stimulates
cholesterol efflux to HDL and apoA-I, inducing an over-expression of the ABCA1 transporter (Ikhlef et al.
2016). Ikhlef et al., who investigated the effects of PPAR gamma, LXR alpha, and ABCA1 inhibitors,
showed that PON1 stimulates cholesterol efflux by over-expressing ABCA1 via the PPARγ-LXRα-ABCA1
pathway (Ikhlef et al. 2016). This process can occur in vivo. In fact, PON1 and oxLDL levels are significantly
higher in atherosclerotic lesions (Mackness B. et al. 1997). The coexistence of PON1 and oxLDL decreases
the atherogenicity of plaque by inhibiting the bioactivity of oxidized lipids (Cohen et al. 2014), while the up-
regulation of ABCA1 expression on macrophages stimulates the efflux of cholesterol from these
macrophages (Ikhlef et al. 2016). An investigation by Ikhlef et al. using transgenic mice that over-express
human PON1 confirmed the involvement of this HDL-associated protein in the stimulation of RCT (Ikhlef et
al. 2017). RCT is significantly higher in transgenic mice over-expressing PON1 than in wild-type mice (Ikhlef
et al. 2017). In addition, HDL from PON1-Tg mice have a higher capacity to mediate cholesterol efflux than
HDL from wild-type mice (Ikhlef et al. 2017). Moreover, macrophages from PON1-Tg mice also express
significantly more ABCA1 transporter than macrophages from wild-type mice (Ikhlef et al. 2017). Thus,
PON1 may stimulate cholesterol efflux via two mechanisms; the first is that PON1 interacts directly with
ABCA1 transporter to allow the efflux of cholesterol to HDL particles (Berrougui et al. 2012) and the second
mechanism suggests that PON1 induces ABCA1 overexpression thereby facilitating the efflux of cholesterol
via this transporter (Berrougui et al. 2012). These in vitro and in vivo studies provided evidence of the
Page 13 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
14
involvement of PON1 in the regulation of many of the anti-atherogenic activities of HDL and showed that
PON1 also modulates HDL functionality.
PON1 and other HDL activities
PON1 has been also suggested to regulate the apoptotic activity of HDL. This process has been
explained by the capacity of PON1, at basal condition, to enhance SR-BI receptor expression on
macrophages via a mechanism implicating LysoPC formation. The increased atherosclerosis development
observed in PON1-deficient mice was explained as a result of reduced SR-BI mediated HDL protection
against apoptosis (Farid et al. 2012; Fuhrman et al. 2010). PON1 was also suggested to regulate the anti-
apoptotic activity of HDL and this effect was explained by the capacity of PON1 to reduce HDL oxidation
(Camps et al. 2010). Ferree et al 2000 demonstrated that enhanced PON1 protein expression was
associated with increased serum biomarker of antiapoptotic activity (Ferre et al. 2006). Some studies have
also associated PON1 to the anti-thrombotic and anti-adhesion activities of HDL and advanced that this
effect may be explained by the capacity of PON1 to protect against oxidation and protein modification.
However, there is not enough convincing data to confirm the involvement of PON1 in the regulation of these
activities of HDL (anti-apoptotic, anti-thrombotic, anti-adhesion activities).
Aging and HDL functionality
It is well established that LDL concentrations and the pro-atherogenic effects of LDL increase with aging
(Abbott et al. 1983; Heiss et al. 1980; Khalil et al. 1996). Conversely, there is no clear agreement regarding
the effect of aging on HDL concentrations (Frishman et al. 1992; Nikkila et al. 1990; Nikkila et al. 1991;
Schaefer et al. 1989; Schaefer, Lamon-Fava, Johnson, et al. 1994; Wallace et al. 1992; Wilson et al. 1994).
Page 14 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
15
While prospective studies have shown that plasma HDL concentrations decline with age, cross-sectional
studies have indicated that mean HDL cholesterol concentrations remain the same, or even increase, with
aging (Wallace et al. 1992). Several other studies have suggested that these variations are gender-
dependent and that, in men, HDL concentrations remain unchanged with aging (Frishman et al. 1992;
Schaefer, Lamon-Fava, Cohn, et al. 1994; Wallace et al. 1992) while they decrease in women starting at
age 60 (Brown et al. 1993; Cheung et al. 2009; Kim et al. 2000). This decrease has been attributed to
hormonal changes in postmenopausal women (Wilson et al. 1994). Changes in the body mass index, in
addition to aging, may also be an important determinant of the decline in HDL concentrations in the elderly.
Some studies have reported that centenarians have HDL concentrations similar to those of middle-aged
healthy populations (Barbagallo et al. 1998). High HDL concentrations have even been reported as having a
positive effect on longevity (Landi et al. 2007). However, other studies have reported lower HDL
concentrations in centenarians (Baggio et al. 1998). This discrepancy has been attributed to differences in
sampling procedures and the nutritional and functional status of the centenarians (Arai et al. 2004).
Pharmacological intervention studies aimed at increasing HDL concentrations as well as studies on genetic
variants that influence HDL concentrations have raised considerable doubt about the relevance of the HDL
concentration hypothesis (Ishigami et al. 1994; Ohta et al. 1995; Yamashita et al. 1990). There is now
general agreement on the importance of HDL functionality (or quality) rather than HDL concentrations in
preventing cardiovascular diseases (Khera et al. 2011; Stock 2011). However, little is know about how HDL
functionality is affected during aging and what impact a decrease in functionality may have on the
development of atherosclerosis in the elderly.
Oxidative modifications of LDL and HDL may play an important role in the pathogenesis of
atherosclerosis. The oxidation of LDL contributes to the accumulation of cholesterol in macrophages,
resulting in their transformation into foam cells. The oxidation of LDL also initiates an inflammatory response
that exacerbates the atherosclerosis process (Ross 1999). We showed that the susceptibility of LDL to
Page 15 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
16
oxidation increases significantly with aging (Khalil et al. 1996). The increase in the susceptibility to oxidation
may be caused by biochemical changes that occur with aging, particularly a decrease in endogenous
vitamin E in LDL and an increase in total polyunsaturated fatty acids (Khalil et al. 1996; Reaven et al. 1999).
HDL from elderly subjects is more susceptible to oxidation and, more importantly, to a significant reduction
in their capacity to prevent LDL oxidation (Jaouad et al. 2006a; Khalil et al. 1998). The reduction in the
antioxidant activity of HDL has been attributed to a reduction in PON1 activity, which is approximately 43%
lower in the elderly (Milochevitch et al. 2001; Seres et al. 2004). Another study in our laboratory showed that
the anti-inflammatory activity of HDL also declines significantly with aging (Loued et al. 2013). Although we
have not clearly proven the involvement of PON1 in the reduction the anti-inflammatory activity of HDL,
some of our results support this hypothesis (Loued et al. 2013). We showed that enriching HDL with PON1
enhances the anti-inflammatory effect of HDL (Figure 2) and that stimulating PON1 paraoxonase activity
improves the anti-inflammatory potential of HDL (Loued et al. 2013).
The ability of HDL to mediate cholesterol efflux is considered the main anti-atherogenic activity of HDL
and is strongly and inversely associated with the severity of atherosclerosis, independently of HDL
cholesterol levels (Khera et al. 2011). The capacity to mediate cholesterol efflux from macrophages is a
metric of HDL functionality (Khera et al. 2011). We showed that HDL from elderly healthy subjects have a
lower capacity to mediate cholesterol efflux (Berrougui et al. 2007). Our results suggested that the alteration
of this HDL activity is due to oxidative modifications of apoA-1, which reduces its interaction with the ABCA1
transporter (Berrougui et al. 2007). However, the subsequent demonstration that PON1 is involved in the
stimulation of the cholesterol efflux capacity of HDL suggests that the decrease in PON1 activity during
aging may explain the alteration of the capacity of HDL from elderly subjects to mediate cholesterol efflux.
Our results from an animal study showed that plasma obtained from 24-month-old mice (aged mice) has a
significant lower capacity to mediate cholesterol efflux from J774 macrophages than plasma obtained from
4-month-old mice (young mice) (Figure 3). Interestingly, the overexpression of PON1 in mice significantly
Page 16 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
17
increases the ability of plasma from both in young and aged mice to mediate cholesterol efflux and also
reduces the age-related difference in the cholesterol efflux capacity of plasma (Figure 3). HDL3 have a
higher PON1 content than HDL2 (Rozek et al. 2005). Interestingly, the decrease with aging in the capacity of
HDL to mediate cholesterol efflux is more closely associated with HDL3 than with HDL2 (Berrougui et al.
2007). This provides additional support for the hypothesis that there is a relationship between PON1 activity
and the capacity of HDL to mediate cholesterol efflux. The reduction in the capacity of HDL to mediate
cholesterol efflux in acute coronary syndrome has also been associated with a reduction of PON1 activity
(Bounafaa et al. 2014).
Our results thus clearly showed that there is a decrease in the main anti-atherogenic activities of HDL in
the elderly, confirming that HDL functionality is altered with aging. The alteration of functionality is also
involved in several risk factors for CVD, in particular in patients with chronic inflammation disorders,
including diabetes mellitus (Morgantini et al. 2011) and atherosclerosis (Navab et al. 1997). Although
several factors may be involved the alteration of HDL functionality, a number of lines of evidence point to
the involvement of PON1 in the regulation of HDL functionality.
HDL functionality and diet
Dietary patterns have been shown to impair or improve HDL functionality. Nutrition studies on HDL
functionality have focused on the antioxidant, anti-inflammatory, antithrombotic, vasodilatory, and RCT
properties of HDL. We recently showed that consumption of extra virgin olive oil, one of the key components
of the Mediterranean diet, improves the antioxidant and anti-inflammatory activities of HDL as well as the
capacity of HDL to remove excess cholesterol from peripheral tissues. Interestingly, these improvements
are accompanied by an increase in PON1 activity (Helal et al. 2013). Other studies have reported that diets
rich in monounsaturated fatty acids (MUFA) are associated with an increase in PON1 activity (Ferretti et al.
2012). In terms of RCT, Treguier et al. reported that the efflux of cholesterol from macrophages to plasma
Page 17 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
18
as well as in vivo RCT are significantly impaired in hamsters fed a cholesterol-enriched diet (Treguier et al.
2011). Nishimoto et al. reported that C57B6/j mice fed fish oil displayed higher in vivo macrophage RCT and
ex vivo efflux to apoA-I than C57B6/j mice fed soybean or coconut oils (Nishimoto et al. 2009). In addition to
macronutrients, the effects of bioactive compounds on HDL functionality have been investigated. We
showed in a recent study that plant-sourced phenolic compounds enhance the anti-atherogenic properties
of HDL by reducing oxidative damage and improving the capacity to promote cholesterol efflux and the RCT
process (Berrougui et al. 2015). Fruit and vegetable intake also modulates HDL functionality. The
consumption of pomegranate juice increases serum PON1 activity and reduces HDL oxidation (Aviram et al.
2000). Other epidemiological studies have shown that vitamin E supplementation improves the RCT
function of HDL in type 2 diabetic individuals (Asleh et al. 2008). On the other hand, the supplementation of
the diets of healthy men with tomato or carrot juice has no effect on PON1 activity (Bub et al. 2005)
Conclusion
CVD is a major health problem, particularly among the elderly. The elderly account for almost 80% of
deaths due to CVD (Garcia-Palmieri 2006; Lakatta 2002). One epidemiological study showed that 0.025 M
step increases in HDL concentrations are associated with 2 to 3% step reductions in the incidence of CVD
(Toth 2005). However, pharmacological intervention studies aimed at increasing plasma HDL
concentrations have led to disappointing results with respect to cardiovascular protection. Given these
results, HDL functionality is increasingly being seen as important, if not more so, than HDL concentrations.
Understanding the parameters that regulate HDL functionality will make it possible to develop new
strategies to reduce the pathogenesis of atherosclerosis, especially in the presence of a risk factor such as
aging. There is some evidence to indicate that PON1 plays an important role in regulating HDL functionality.
Page 18 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
19
However, further studies are required to determine the mechanisms by which PON1 improves HDL
functionality and protects against CVD.
Acknowledgment
This work was supported by grants from the Canadian Institutes of Health Research (MOP-89912 and IAO-
134212).
Page 19 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
20
References:
Abbott, R. D., Garrison, R. J., Wilson, P. W., Epstein, F. H., Castelli, W. P., Feinleib, M. et al. 1983. Joint
distribution of lipoprotein cholesterol classes. The Framingham study. Arteriosclerosis. 3(3): 260-272.
Aharoni, S., Aviram, M., Fuhrman, B. 2013. Paraoxonase 1 (PON1) reduces macrophage inflammatory
responses. Atherosclerosis. 228(2): 353-361.
Ahmed, Z., Ravandi, A., Maguire, G. F., Emili, A., Draganov, D., La Du, B. N. et al. 2002. Multiple substrates
for paraoxonase-1 during oxidation of phosphatidylcholine by peroxynitrite. Biochem Biophys Res Commun.
290(1): 391-396.
Ahmed, Z., Babaei, S., Maguire, G. F., Draganov, D., Kuksis, A., La Du, B. N. et al. 2003. Paraoxonase-1
reduces monocyte chemotaxis and adhesion to endothelial cells due to oxidation of palmitoyl, linoleoyl
glycerophosphorylcholine. Cardiovasc Res. 57(1): 225-231.
Akita, H., Chiba, H., Tsuchihashi, K., Tsuji, M., Kumagai, M., Matsuno, K. et al. 1994. Cholesteryl ester
transfer protein gene: two common mutations and their effect on plasma high-density lipoprotein cholesterol
content. J Clin Endocrinol Metab. 79(6): 1615-1618.
Alexander, E. T., Tanaka, M., Kono, M., Saito, H., Rader, D. J., Phillips, M. C. 2009. Structural and
functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I. J lipid Res. 50(7):
1409-1419.
Ansell, B. J., Navab, M., Hama, S., Kamranpour, N., Fonarow, G., Hough, G. et al. 2003.
Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control
subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin
treatment. Circulation. 108(22): 2751-2756.
Arai, Y., Hirose, N. 2004. Aging and HDL metabolism in elderly people more than 100 years old. J
Atheroscler Thromb. 11(5): 246-252.
Page 20 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
21
Asleh, R., Blum, S., Kalet-Litman, S., Alshiek, J., Miller-Lotan, R., Asaf, R. et al. 2008. Correction of HDL
dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes. 57(10): 2794-2800.
Asztalos, B. F., Schaefer, E. J., Horvath, K. V., Yamashita, S., Miller, M., Franceschini, G. et al. 2007. Role
of LCAT in HDL remodeling: investigation of LCAT deficiency states. J lipid Res. 48(3): 592-599.
Aviram, M., Billecke, S., Sorenson, R., Bisgaier, C., Newton, R., Rosenblat, M. et al. 1998. Paraoxonase
active site required for protection against LDL oxidation involves its free sulfhydryl group and is different
from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase
allozymes Q and R. Arterioscler Thromb Vasc Biol. 18(10): 1617-1624.
Aviram, M., Dornfeld, L., Rosenblat, M., Volkova, N., Kaplan, M., Coleman, R. et al. 2000. Pomegranate
juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation:
studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr. 71(5): 1062-1076.
Baggio, G., Donazzan, S., Monti, D., Mari, D., Martini, S., Gabelli, C. et al. 1998. Lipoprotein(a) and
lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factors. FASEB J. 12(6): 433-437.
Barbagallo, C. M., Averna, M. R., Frada, G., Noto, D., Cavera, G., Notarbartolo, A. 1998. Lipoprotein profile
and high-density lipoproteins: subfractions distribution in centenarians. Gerontology. 44(2): 106-110.
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J., Komajda, M. et al. 2007. Effects of
torcetrapib in patients at high risk for coronary events. N Engl J Med. 357(21): 2109-2122.
Berard, A. M., Foger, B., Remaley, A., Shamburek, R., Vaisman, B. L., Talley, G. et al. 1997. High plasma
HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-
cholesteryl acyltransferase. Nat Med. 3(7): 744-749.
Berard, A. M., Clerc, M., Brewer, B., Jr., Santamarina-Fojo, S. 2001. A normal rate of cellular cholesterol
removal can be mediated by plasma from a patient with familial lecithin-cholesterol acyltransferase (LCAT)
deficiency. Clin Chim Acta. 314(1-2): 131-139.
Page 21 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
22
Berrougui, H., Isabelle, M., Cloutier, M., Grenier, G., Khalil, A. 2007. Age-related impairment of HDL-
mediated cholesterol efflux. J Lipid Res. 48(2): 328-336.
Berrougui, H., Loued, S., Khalil, A. 2012. Purified human paraoxonase-1 interacts with plasma membrane
lipid rafts and mediates cholesterol efflux from macrophages. Free Radic Biol Med. 52(8): 1372-1381.
Berrougui, H., Ikhlef, S., Khalil, A. 2015. Extra Virgin Olive Oil Polyphenols Promote Cholesterol Efflux and
Improve HDL Functionality. Evid Based Complement Alternat Med. 2015: 208062.
Boekholdt, S. M., Thompson, J. F. 2003. Natural genetic variation as a tool in understanding the role of
CETP in lipid levels and disease. J Lipid Res. 44(6): 1080-1093.
Bonnefont-Rousselot, D., Khalil, A., Delattre, J., Jore, D., Gardes-Albert, M. 1997. Oxidation of human high-
density lipoproteins by .OH and .OH/O(.-)2 free radicals. Rad Res. 147(6): 721-728.
Bonnefont-Rousselot, D., Khalil, A., Gardes-Albert, M., Delattre, J. 1997. Reciprocal protection of LDL and
HDL oxidised by .OH free radicals in the presence of oxygen. FEBS Lett. 403(1): 70-74.
Bounafaa, A., Berrougui, H., Ikhlef, S., Essamadi, A., Nasser, B., Bennis, A. et al. 2014. Alteration of HDL
functionality and PON1 activities in acute coronary syndrome patients. Clin Biochem. 47(18): 318-325.
Brown, S. A., Hutchinson, R., Morrisett, J., Boerwinkle, E., Davis, C. E., Gotto, A. M., Jr. et al. 1993. Plasma
lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis
Risk in Communities (ARIC) Study. Arterioscler Thromb. 13(8): 1139-1158.
Brunham, L. R., Kruit, J. K., Iqbal, J., Fievet, C., Timmins, J. M., Pape, T. D. et al. 2006. Intestinal ABCA1
directly contributes to HDL biogenesis in vivo. J Clin Invest. 116(4): 1052-1062.
Brushia, R. J., Forte, T. M., Oda, M. N., La Du, B. N., Bielicki, J. K. 2001. Baculovirus-mediated expression
and purification of human serum paraoxonase 1A. J Lipid Res. 42(6): 951-958.
Bub, A., Barth, S. W., Watzl, B., Briviba, K., Rechkemmer, G. 2005. Paraoxonase 1 Q192R (PON1-192)
polymorphism is associated with reduced lipid peroxidation in healthy young men on a low-carotenoid diet
supplemented with tomato juice. Br J Nutr. 93(3): 291-297.
Page 22 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
23
Calabresi, L., Pisciotta, L., Costantin, A., Frigerio, I., Eberini, I., Alessandrini, P. et al. 2005. The molecular
basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and
biochemical findings in 13 unrelated Italian families. Arterioscler Thromb Vasc Biol. 25(9): 1972-1978.
Calabresi, L., Favari, E., Moleri, E., Adorni, M. P., Pedrelli, M., Costa, S. et al. 2009. Functional LCAT is not
required for macrophage cholesterol efflux to human serum. Atherosclerosis. 204(1): 141-146.
Calabresi, L., Simonelli, S., Gomaraschi, M., Franceschini, G. 2012. Genetic lecithin:cholesterol
acyltransferase deficiency and cardiovascular disease. Atherosclerosis. 222(2): 299-306.
Camps, J., Marsillach, J., Rull, A., Alonso-Villaverde, C., Joven, J. 2010. Interrelationships between
paraoxonase-1 and monocyte chemoattractant protein-1 in the regulation of hepatic inflammation. Adv Exp
Med Biol. 660: 5-18.
Cherki, M., Berrougui, H., Isabelle, M., Cloutier, M., Koumbadinga, G. A., Khalil, A. 2007. Effect of PON1
polymorphism on HDL antioxidant potential is blunted with aging. Exp Gerontol. 42(8): 815-824.
Cheung, B. M., Li, M., Ong, K. L., Wat, N. M., Tam, S., Pang, R. W. et al. 2009. High density lipoprotein-
cholesterol levels increase with age in American women but not in Hong Kong Chinese women. Clin
Endocrinol (Oxf). 70(4): 561-568.
Chroni, A., Liu, T., Gorshkova, I., Kan, H. Y., Uehara, Y., Von Eckardstein, A. et al. 2003. The central
helices of ApoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux. Amino
acid residues 220-231 of the wild-type ApoA-I are required for lipid efflux in vitro and high density lipoprotein
formation in vivo. J Biol Chem. 278(9): 6719-6730.
Cohen, E., Aviram, M., Khatib, S., Artoul, F., Rabin, A., Mannheim, D. et al. 2014. Human carotid plaque
phosphatidylcholine specifically interacts with paraoxonase 1, increases its activity, and enhances its uptake
by macrophage at the expense of its binding to HDL. Free Radic Biol Med. 76C: 14-24.
Connelly, P. W., Draganov, D., Maguire, G. F. 2005. Paraoxonase-1 does not reduce or modify oxidation of
phospholipids by peroxynitrite. Free Radic Biol Med. 38(2): 164-174.
Page 23 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
24
de Beer, M. C., Ji, A., Jahangiri, A., Vaughan, A. M., de Beer, F. C., van der Westhuyzen, D. R. et al. ATP
binding cassette G1-dependent cholesterol efflux during inflammation. J Lipid Res. 52(2): 345-353.
de Beer, M. C., Ji, A., Jahangiri, A., Vaughan, A. M., de Beer, F. C., van der Westhuyzen, D. R. et al. 2011.
ATP binding cassette G1-dependent cholesterol efflux during inflammation. J Lipid Res. 52(2): 345-353.
Elkhalil, L., Majd, Z., Bakir, R., Perez-Mendez, O., Castro, G., Poulain, P. et al. 1997. Fish-eye disease:
structural and in vivo metabolic abnormalities of high-density lipoproteins. Metabolism. 46(5): 474-483.
Esterbauer, H., Schmidt, R., Hayn, M. 1997. Relationships among oxidation of low-density lipoprotein,
antioxidant protection, and atherosclerosis. Adv Pharmacol. 38: 425-456.
Farid, A. S., Horii, Y. 2012. Modulation of paraoxonases during infectious diseases and its potential impact
on atherosclerosis. Lipids Health Dis. 11: 92.
Ferre, N., Marsillach, J., Camps, J., Mackness, B., Mackness, M., Riu, F. et al. 2006. Paraoxonase-1 is
associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J Hepatol. 45(1): 51-
59.
Ferretti, G., Bacchetti, T. 2012. Effect of dietary lipids on paraoxonase-1 activity and gene expression. Nutr
Metab Cardiovasc Dis. 22(2): 88-94.
Frikke-Schmidt, R., Nordestgaard, B. G., Stene, M. C., Sethi, A. A., Remaley, A. T., Schnohr, P. et al. 2008.
Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels
and risk of ischemic heart disease. JAMA. 299(21): 2524-2532.
Frishman, W. H., Ooi, W. L., Derman, M. P., Eder, H. A., Gidez, L. I., Ben-Zeev, D. et al. 1992. Serum lipids
and lipoproteins in advanced age. Intraindividual changes. Ann Epidemiol. 2(1-2): 43-50.
Fuhrman, B., Gantman, A., Aviram, M. 2010. Paraoxonase 1 (PON1) deficiency in mice is associated with
reduced expression of macrophage SR-BI and consequently the loss of HDL cytoprotection against
apoptosis. Atherosclerosis. 211(1): 61-68.
Page 24 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
25
Garcia-Palmieri, M. R. 2006. Evidence based secondary prevention of coronary artery disease in the
elderly--2006. P R Health Sci J. 25(3): 229-239.
Gbandjaba, N. Y., Ghalim, N., Hassar, M., Berrougui, H., Labrazi, H., Taki, H. et al. 2012. Paraoxonase
activity in healthy, diabetic, and hemodialysis patients. Clin Biochem. 45(6): 470-474.
Glomset, J. A. 1968. The plasma lecithins:cholesterol acyltransferase reaction. J lipid Res. 9(2), 155-167.
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., Dawber, T. R. 1977. High density lipoprotein as
a protective factor against coronary heart disease. The Framingham Study. Am J Med. 62(5): 707-714.
Goyal, J., Wang, K., Liu, M., Subbaiah, P. V. 1997. Novel function of lecithin-cholesterol acyltransferase.
Hydrolysis of oxidized polar phospholipids generated during lipoprotein oxidation. J Biol Chem. 272(26):
16231-16239.
Gu, X., Huang, Y., Levison, B. S., Gerstenecker, G., DiDonato, A. J., Hazen, L. B. et al. 2016. Identification
of Critical Paraoxonase 1 Residues Involved in High Density Lipoprotein Interaction. J Biol Chem. 291(4):
1890-1904.
Haase, C. L., Tybjaerg-Hansen, A., Qayyum, A. A., Schou, J., Nordestgaard, B. G., Frikke-Schmidt, R.
2012. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of
HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab. 97(2): E248-256.
Haghpassand, M., Bourassa, P. A., Francone, O. L., Aiello, R. J. 2001. Monocyte/macrophage expression
of ABCA1 has minimal contribution to plasma HDL levels. J Clin Invest. 108(9): 1315-1320.
Harel, M., Aharoni, A., Gaidukov, L., Brumshtein, B., Khersonsky, O., Meged, R. et al. 2004. Structure and
evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol
Biol. 11(5): 412-419.
Heiss, G., Tamir, I., Davis, C. E., Tyroler, H. A., Rifkand, B. M., Schonfeld, G. et al. 1980. Lipoprotein-
cholesterol distributions in selected North American populations: the lipid research clinics program
prevalence study. Circulation. 61(2): 302-315.
Page 25 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
26
Helal, O., Berrougui, H., Loued, S., Khalil, A. 2013. Extra-virgin olive oil consumption improves the capacity
of HDL to mediate cholesterol efflux and increases ABCA1 and ABCG1 expression in human macrophages.
Br J Nutr. 109(10): 1844-1855.
Hiura, Y., Shen, C. S., Kokubo, Y., Okamura, T., Morisaki, T., Tomoike, H. et al. 2009. Identification of
genetic markers associated with high-density lipoprotein-cholesterol by genome-wide screening in a
Japanese population: the Suita study. Circ J. 73(6): 1119-1126.
Ikhlef, S., Berrougui, H., Kamtchueng Simo, O., Khalil, A. 2016. Paraoxonase 1-treated oxLDL promotes
cholesterol efflux from macrophages by stimulating the PPARgamma-LXRalpha-ABCA1 pathway. FEBS
Lett. 590: (11): 1614-1629.
Ikhlef, S., H, B., Khalil, A. 2017. Human paraoxonase 1 overexpression in mice stimulates HDL cholesterol
efflux and reverse cholesterol transport. PLOS ONE. 12(3): e0173385
Inazu, A., Brown, M. L., Hesler, C. B., Agellon, L. B., Koizumi, J., Takata, K. et al. 1990. Increased high-
density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J
Med. 323(18): 1234-1238.
Ishigami, M., Yamashita, S., Sakai, N., Arai, T., Hirano, K., Hiraoka, H. et al. 1994. Large and cholesteryl
ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect
macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J Biochem.
116(2): 257-262.
Jaouad, L., de Guise, C., Berrougui, H., Cloutier, M., Isabelle, M., Fulop, T. et al. 2006a. Age-related
decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydyl
groups. Atherosclerosis. 185(1): 191-200.
Jaouad, L., de Guise, C., Berrougui, H., Cloutier, M., Isabelle, M., Fulop, T. et al. 2006b. Age-related
decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydryl
groups. Atherosclerosis. 185(1): 191-200.
Page 26 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
27
Ji, A., Meyer, J. M., Cai, L., Akinmusire, A., de Beer, M. C., Webb, N. R. et al. 2011. Scavenger receptor
SR-BI in macrophage lipid metabolism. Atherosclerosis. 217(1): 106-112.
Johnson, W. J., Mahlberg, F. H., Rothblat, G. H., Phillips, M. C. 1991. Cholesterol transport between cells
and high-density lipoproteins. Biochim et biophys acta. 1085(3): 273-298.
Jonas, A. 2000. Lecithin cholesterol acyltransferase. Biochimica et biophysica acta. 1529: (1-3): 245-256.
Khalil, A., Wagner, J. R., Lacombe, G., Dangoisse, V., Fulop, T., Jr. 1996. Increased susceptibility of low-
density lipoprotein (LDL) to oxidation by gamma-radiolysis with age. FEBS Lett. 392(1): 45-48.
Khalil, A., Jay-Gerin, J. P., Fulop, T., Jr. 1998. Age-related increased susceptibility of high-density
lipoproteins (HDL) to in vitro oxidation induced by gamma-radiolysis of water. FEBS Lett. 435(2-3): 153-158.
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K. et al. 2011. Cholesterol
efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 364(2): 127-135.
Kim, C. J., Kim, T. H., Ryu, W. S., Ryoo, U. H. 2000. Influence of menopause on high density lipoprotein-
cholesterol and lipids. J Korean Med Sci. 15(4): 380-386.
Koizumi, J., Mabuchi, H., Yoshimura, A., Michishita, I., Takeda, M., Itoh, H. et al. 1985. Deficiency of serum
cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis. 58(1-
3): 175-186.
Lakatta, E. G. 2002. Age-associated cardiovascular changes in health: impact on cardiovascular disease in
older persons. Heart Fail Rev. 7(1), 29-49.
Lambert, G., Sakai, N., Vaisman, B. L., Neufeld, E. B., Marteyn, B., Chan, C. C. et al. 2001. Analysis of
glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice. J Biol Chem.
276(18): 15090-15098.
Landi, F., Russo, A., Pahor, M., Capoluongo, E., Liperoti, R., Cesari, M. et al. 2007. Serum High-Density
Lipoprotein Cholesterol Levels and Mortality in Frail, Community-Living Elderly. Gerontology. 54(2): 71-8.
Page 27 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
28
Loued, S., Isabelle, M., Berrougui, H., Khalil, A. 2012. The anti-inflammatory effect of paraoxonase 1
against oxidized lipids depends on its association with high density lipoproteins. Life Sciences. 90(1-2): 82-
88.
Loued, S., Berrougui, H., Componova, P., Ikhlef, S., Helal, O., Khalil, A. 2013. Extra-virgin olive oil
consumption reduces the age-related decrease in HDL and paraoxonase 1 anti-inflammatory activities. Br J
Nutr. 110(7): 1272-1284.
Mackness, B., Hunt, R., Durrington, P. N., Mackness, M. I. 1997. Increased immunolocalization of
paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of
atherosclerosis. Arterioscler Thromb Vasc Biol. 17(7): 1233-1238.
Mackness, B., Durrington, P. N., Mackness, M. I. 1998. Human serum paraoxonase. Gen Pharmacol. 31(3):
329-336.
Mackness, M. I., Arrol, S., Durrington, P. N. 1991. Paraoxonase prevents accumulation of lipoperoxides in
low-density lipoprotein. FEBS Lett. 286(1-2): 152-154.
Mehlum, A., Muri, M., Hagve, T. A., Solberg, L. A., Prydz, H. 1997. Mice overexpressing human lecithin:
cholesterol acyltransferase are not protected against diet-induced atherosclerosis. APMIS. 105(11): 861-
868.
Milochevitch, C., Khalil, A. 2001. Study of the paraoxonase and platelet-activating factor acetylhydrolase
activities with aging. Prostaglandins Leukot Essent Fatty Acids. 65(5-6): 241-246.
Morgantini, C., Natali, A., Boldrini, B., Imaizumi, S., Navab, M., Fogelman, A. M. et al. 2011. Anti-
inflammatory and Antioxidant Properties of HDLs Are Impaired in Type 2 Diabetes. Diabetes. 60(10): 2617-
2623.
Navab, M., Hama-Levy, S., Van Lenten, B. J., Fonarow, G. C., Cardinez, C. J., Castellani, L. W. et al. 1997.
Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest. 99(8): 2005-
2019.
Page 28 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
29
Ng, D. S., Chu, T., Esposito, B., Hui, P., Connelly, P. W., Gross, P. L. 2008. Paraoxonase-1 deficiency in
mice predisposes to vascular inflammation, oxidative stress, and thrombogenicity in the absence of
hyperlipidemia. Cardiovasc Pathol. 17(4): 226-232.
Nikkila, M., Heikkinen, J. 1990. High-density lipoprotein cholesterol and longevity. Age Ageing. 19(2): 119-
124.
Nikkila, M., Pitkajarvi, T., Koivula, T., Heikkinen, J. 1991. Elevated high-density-lipoprotein cholesterol and
normal triglycerides as markers of longevity. Klin Wochenschr. 69(17): 780-785.
Nishimoto, T., Pellizzon, M. A., Aihara, M., Stylianou, I. M., Billheimer, J. T., Rothblat, G. et al. 2009. Fish oil
promotes macrophage reverse cholesterol transport in mice. Arterioscler Thromb Vasc Biol. 29(10): 1502-
1508.
Ohta, T., Nakamura, R., Takata, K., Saito, Y., Yamashita, S., Horiuchi, S. et al. 1995. Structural and
functional differences of subspecies of apoA-I-containing lipoprotein in patients with plasma cholesteryl
ester transfer protein deficiency. J Lipid Res. 36(4): 696-704.
Perez-Jimenez, F., Lopez-Miranda, J. 2005. [University of Health Sciences: a blow of hope]. Med Clin
(Barc). 125(12): 477.
Rader, D. J. 2007. Illuminating HDL--is it still a viable therapeutic target? The New England journal of
medicine. 357(21): 2180-2183.
Reaven, P. D., Napoli, C., Merat, S., Witztumc, J. L. 1999. Lipoprotein modification and atherosclerosis in
aging. Exp Gerontol. 34(4): 527-537.
Remaley, A. T., Stonik, J. A., Demosky, S. J., Neufeld, E. B., Bocharov, A. V., Vishnyakova, T. G. et al.
2001. Apolipoprotein specificity for lipid efflux by the human ABCAI transporter. Biochem Biophys Res
Commun. 280(3): 818-823.
Page 29 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
30
Roma, P., Gregg, R. E., Meng, M. S., Ronan, R., Zech, L. A., Franceschini, G. et al. 1993. In vivo
metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with familial
hypoalphalipoproteinemia. J Clin Invest. 91(4): 1445-1452.
Romanchik, J. E., Morel, D. W., Harrison, E. H. 1995. Distributions of carotenoids and alpha-tocopherol
among lipoproteins do not change when human plasma is incubated in vitro. J Nutr. 125(10): 2610-2617.
Rosenblat, M., Gaidukov, L., Khersonsky, O., Vaya, J., Oren, R., Tawfik, D. S. et al. 2006. The catalytic
histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-
mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J
Biol Chem. 281(11): 7657-7665.
Ross, R. 1999. Atherosclerosis--an inflammatory disease. N Engl J Med. 340(2): 115-126.
Rozek, L. S., Hatsukami, T. S., Richter, R. J., Ranchalis, J., Nakayama, K., McKinstry, L. A. et al. 2005. The
correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease
status. J Lipid Res. 46(9): 1888-1895.
Rozenberg, O., Shih, D. M., Aviram, M. 2003. Human serum paraoxonase 1 decreases macrophage
cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine
formation. Arterioscler Thromb Vasc Biol. 23(3): 461-467.
Schaefer, E. J., Moussa, P. B., Wilson, P. W., McGee, D., Dallal, G., Castelli, W. P. 1989. Plasma
lipoproteins in healthy octogenarians: lack of reduced high density lipoprotein cholesterol levels: results
from the Framingham Heart Study. Metabolism: clinical and experimental. 38(4): 293-296.
Schaefer, E. J., Lamon-Fava, S., Cohn, S. D., Schaefer, M. M., Ordovas, J. M., Castelli, W. P. et al. 1994.
Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and
apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res. 35: (5): 779-792.
Page 30 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
31
Schaefer, E. J., Lamon-Fava, S., Johnson, S., Ordovas, J. M., Schaefer, M. M., Castelli, W. P. et al. 1994.
Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma
lipoprotein levels. Results from the Framingham Offspring Study. Arterioscler Thromb. 14(7): 1105-1113.
Schilling, T., Eder, C. 2009. Lysophosphatidylcholine- and MCP-1-induced chemotaxis of monocytes
requires potassium channel activity. Pflugers Arch. 459(1): 71-77.
Seres, I., Freyss-Beguin, M., Mohacsi, A., Kozlovsky, B., Simon, J., Devynck, M. A. et al. 1996. Alteration of
lymphocyte membrane phospholipids and intracellular free calcium concentrations in hyperlipidemic
subjects. Atherosclerosis. 121(2): 175-183.
Seres, I., Paragh, G., Deschene, E., Fulop, T., Jr., Khalil, A. 2004. Study of factors influencing the
decreased HDL associated PON1 activity with aging. Exp Gerontol. 39(1): 59-66.
Shih, D. M., Gu, L., Xia, Y. R., Navab, M., Li, W. F., Hama, S. et al. 1998. Mice lacking serum paraoxonase
are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394: (6690), 284-287.
Stock, J. 2011. Importance of HDL functionality to cardiovascular risk. Atherosclerosis. 218(1): 19-20.
Subbaiah, P. V., Liu, M. 1996. Comparative studies on the substrate specificity of lecithin:cholesterol
acyltransferase towards the molecular species of phosphatidylcholine in the plasma of 14 vertebrates. J
Lipid Res. 37(1): 113-122.
Sviridov, D., Nestel, P. 2002. Dynamics of reverse cholesterol transport: protection against atherosclerosis.
Atherosclerosis. 161(2): 245-254.
Sviridov, D., Mukhamedova, N., Remaley, A. T., Chin-Dusting, J., Nestel, P. 2008. Antiatherogenic
functionality of high density lipoprotein: how much versus how good. J Atheroscler Thromb. 15(2): 52-62.
Tall, A. R. 1993. Plasma cholesteryl ester transfer protein. J Lipid Res. 34(8): 1255-1274.
Tanigawa, H., Billheimer, J. T., Tohyama, J., Fuki, I. V., Ng, D. S., Rothblat, G. H. et al. 2009. Lecithin:
cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in
vivo. Circulation. 120(2): 160-169.
Page 31 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
32
Teiber, J. F., Draganov, D. I., La Du, B. N. 2004. Purified human serum PON1 does not protect LDL against
oxidation in the in vitro assays initiated with copper or AAPH. J Lipid Res. 45(12): 2260-2268.
Timmins, J. M., Lee, J. Y., Boudyguina, E., Kluckman, K. D., Brunham, L. R., Mulya, A. et al. 2005.
Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney
hypercatabolism of apoA-I. J Clin Invest. 115(5): 1333-1342.
Toth, P. P. 2005. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies.
Am J Cardiol. 96(9A): 50K-58K.
Treguier, M., Briand, F., Boubacar, A., Andre, A., Magot, T., Nguyen, P. et al. 2011. Diet-induced
dyslipidemia impairs reverse cholesterol transport in hamsters. Eur J Clin Invest. 41(9): 921-928.
Tsompanidi, E. M., Brinkmeier, M. S., Fotiadou, E. H., Giakoumi, S. M., Kypreos, K. E. 2010. HDL
biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis. 208(1): 3-9.
Tward, A., Xia, Y. R., Wang, X. P., Shi, Y. S., Park, C., Castellani, L. W. et al. 2002. Decreased
atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 106(4): 484-
490.
Wallace, R. B., Colsher, P. L. 1992. Blood lipid distributions in older persons. Prevalence and correlates of
hyperlipidemia. Ann Epidemiol. 2(1-2): 15-21.
Wang, N., Silver, D. L., Costet, P., Tall, A. R. 2000. Specific binding of ApoA-I, enhanced cholesterol efflux,
and altered plasma membrane morphology in cells expressing ABC1. The Journal of biological chemistry.
275(42): 33053-33058.
Wang, X., Rader, D. J. 2007. Molecular regulation of macrophage reverse cholesterol transport. Curr Opin
Cardiol. 22(4): 368-372.
Wilson, P. W., Anderson, K. M., Harris, T., Kannel, W. B., Castelli, W. P. 1994. Determinants of change in
total cholesterol and HDL-C with age: the Framingham Study. J Gerontol. 49(6): M252-257.
Page 32 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
33
Xie, Q., Zhao, S. 2011. [Effect of apolipoprotein A-I mimetic peptides on cholesterol efflux in RAW264.7
cells]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 36(1): 51-57.
Yamashita, S., Sprecher, D. L., Sakai, N., Matsuzawa, Y., Tarui, S., Hui, D. Y. 1990. Accumulation of
apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma
cholesteryl ester transfer protein deficiency. J Clin Invest. 86(3): 688-695.
Yancey, P. G., Bortnick, A. E., Kellner-Weibel, G., de la Llera-Moya, M., Phillips, M. C., Rothblat, G. H.
2003. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol. 23(5):
712-719.
Yvan-Charvet, L., Matsuura, F., Wang, N., Bamberger, M. J., Nguyen, T., Rinninger, F. et al. 2007.
Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol
efflux to HDL. Arterioscler Thromb Vasc Biol. 27(5): 1132-1138.
Yvan-Charvet, L., Wang, N., Tall, A. R. 2010. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol
efflux and immune responses. Arterioscler Thromb Vasc Biol. 30(2): 139-143.
Page 33 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
34
Fig. 1: Summary of the anti-atherogenic activities of HDL
Fig. 2. Assessment of the anti-inflammatory effect of PON1 on Ea.hy926 endothelial cells and the
interaction of PON1 with LCAT
Oxidized HDL (oxHDL) were generated by exposing HDL to oxygen free radicals produced by the gamma
radiolysis of water. The oxHDL were pre-incubated with PON1 or with PON1 and LCAT for 4 h. They were
then incubated with Ea.hy926 endothelial cells. PON1 was used at a concentration of 50 µg/mL and LCAT
at a concentration of 5 µg/mL. Data are expressed as means ± SEM. Mean values were compared using
one way ANOVA followed by Bonferroni's multiple comparison post test. *** p < 0.001 with respect to
oxHDL alone.
Fig. 3. PON1 overexpression in mice increases the capacity plasma to mediate cholesterol efflux
from macrophages
J774 macrophages (1 x 106 cells/mL) were loaded with [3H]-cholesterol (2 µCi/mL) for 24 h. Plasma
samples obtained from WT and PON1-Tg mice were treated with polyethylene glycol to precipitate ApoB-
100-containing particles and were then incubated with J774 macrophages for 24 h. Cholesterol efflux
(radiolabeled cholesterol released from cells) was calculated using the following formula: (radioactivity
(cpm) in supernatant/radioactivity (cpm) in cells + medium) × 100. Data are expressed as means ± SEM.
*p<0.03 and ***p<0.003.
Page 34 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
Figure 1
.
Antioxidant
Reverse cholesterol transport
An#-‐thrombo#c
Regula#on of endothelial func#on
Immuno-‐modula#on
An#-‐inflammatory
An#-‐apopto#c
Page 35 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
Figure 2
0
10
20
30
40
oxHDL oxHDL+ PON1
oxHDL+ PON1 & LCAT
***
***
Baseline PON1
ICA
M e
xpre
ssio
n (%
vs
base
)
Page 36 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology
Draft
0
10
20
30
Wild-type young mice
Wild-type aged mice
PON1-Tgyoung mice
PON1-Tgaged mice
Cho
lest
erol
effe
ux to
J77
4 m
acro
phag
es(%
of r
adilo
abel
ed c
hole
ster
ol)
*
*
***
Figure 3Page 37 of 37
https://mc06.manuscriptcentral.com/cjpp-pubs
Canadian Journal of Physiology and Pharmacology